Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14095769 | 0.87 | MEN1 (0.38) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL15745438 | 0.84 | MEN1 (0.48) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL18888509 | 0.83 | KMT2A (0.45) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL5070505 | 0.83 | KMT2A (0.40) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL15745440 | 0.82 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL5403745 | 0.81 | MEN1 (0.44) | MEN1GAAKMT2ATDP1SERPINE1 | |
| Ammonia Solution, Strong SCHEMBL8577516 | 0.80 | MEN1 (0.49) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL23366841 | 0.78 | MEN1 (0.47) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL1222568 | 0.78 | MEN1 (0.44) | MEN1GAAKMT2ATDP1SERPINE1 | |
| SCHEMBL1222570 | 0.78 | MEN1 (0.44) | MEN1GAAKMT2ATDP1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | MEN1 3420/4885GAA 254/4885KMT2A 3305/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | MEN1 3609/4885GAA 202/4885KMT2A 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.